Esperion Therapeutics to Present at the Stifel 2016 Healthcare Conference
November 09 2016 - 4:30PM
Presentation and Webcast on Wednesday, November
16, 2016 at 3:00 p.m. Eastern Time
Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company
focused on developing and commercializing oral therapies for the
treatment of patients with elevated low density lipoprotein
cholesterol (LDL-C), today announced that president and chief
executive officer, Tim M. Mayleben, will present at the Stifel 2016
Healthcare Conference in New York City on Wednesday, November 16,
2016 at 3:00 p.m. Eastern Time.
A live, listen-only webcast of the presentation can be accessed
on the investor relations section of the Esperion website
at www.esperion.com. A webcast replay of the presentation will
be archived on the Company's website for 90 days following the
event.
About Bempedoic Acid
Bempedoic acid is a first-in-class ACL inhibitor that reduces
cholesterol biosynthesis and lowers elevated levels of LDL-C by
up-regulating the LDL receptor, but with reduced potential for
muscle-related side effects. Completed Phase 1 and 2 studies in
more than 800 patients treated with bempedoic acid have produced
clinically relevant LDL-C lowering results of up to 30 percent as
monotherapy, approximately 50 percent in combination with
ezetimibe, and an incremental 20 to 22 percent when added to stable
statin therapy.
Esperion’s Commitment to Patients with
Hypercholesterolemia
In the United States, 78 million people, or more than 20 percent
of the population, have elevated LDL-C; an additional 73 million
people in Europe and 30 million people in Japan also live with
elevated LDL-C. Esperion’s mission is to provide patients and
physicians with a new oral therapy to significantly reduce elevated
levels of LDL-C in patients inadequately treated with current
lipid-modifying therapies. Esperion-discovered and developed,
bempedoic acid is an oral LDL-C lowering therapy in Phase 3
development. The Company plans to develop bempedoic acid as a
monotherapy as well as a fixed dose combination (FDC) with
ezetimibe, with a particular focus on patients inadequately treated
with current lipid-modifying therapies. It is estimated that
approximately 5-20 percent of patients who are prescribed statins
are only able to tolerate less than the lowest approved daily
starting dose of their statin (“statin intolerant”).
About Esperion Therapeutics
Esperion Therapeutics, Inc. is a pharmaceutical company
focused on developing and commercializing oral therapies for the
treatment of patients with elevated LDL-C. Through scientific and
clinical excellence, and a deep understanding of cholesterol
biology, the team at Esperion is committed to developing new LDL-C
lowering therapies that will make a substantial impact on reducing
global cardiovascular disease; the leading cause of death around
the world. Bempedoic acid, the Company’s lead product candidate,
significantly reduces elevated LDL-C levels in patients with
hypercholesterolemia, including patients inadequately treated with
current lipid-modifying therapies. For more information, please
visit www.esperion.com and follow us on Twitter
at https://twitter.com/EsperionInc.
Media Contact:
Audrey Gross
W2O Group
212.301.7214
agross@w2ogroup.com
Investor Contact:
Mindy Lowe
Esperion Therapeutics, Inc.
734.887.3903
mlowe@esperion.com
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Apr 2023 to Apr 2024